EDErik Trovão Diniz

Erik Trovão Diniz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erik Trovão Diniz has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dyslipidemia

    by Erik T. Diniz, Francisco Bandeira


  • Primary Hyperparathyroidism is Associated With subclinical Peripheral Neural Alterations

    by Erik Trovão Diniz, Francisco Bandeira, Otávio Gomes Lins, Érica Nogueira Bezerra Cavalcanti, Tiago Matos de Arruda, Alexandre Medeiros Sampaio Januário, Kaisa Trovão Diniz, Thyciara Fontenele Marques, Hildo Azevedo


    • 18 May 2011
      • Vol. 51  (2) , 131-7

    Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica.

    by Tatiana Clementino Pinto Toscano De França, Luiz Griz, Jorge Pinho, Erik Trovão Diniz, Luena Dias De Andrade, Cynthia Salgado Lucena, Susyane Ribeiro Beserra, Nadja Maria Jorge Asano, Angela Pinto Duarte, Francisco Bandeira

    To assess the effect of bisphosphonates on post-parathyroidectomy hypocalcemia in patients with osteitis fibrosa cystica. Review of the medical records of six patients using bisphosphonates preoperatively. Mean age was 35.6 ± 10.5 years; serum calcium = 13.51 + 0.87 mg/dL; iPTH = 1,389 + 609 pg/mL. The mean value of urine deoxypyridinoline (UDPD) of three patients was 131 ± 183 nmol/mmol Cr, and of C-telopeptide (CTX), 2,253 ± 1,587 pg/mL. The mean values of bone densitometry (T score) were as follows: 0.673 ± 0.150 g/cm(2) (-4.42 ± 1.23) in lumbar spine (L2-L4); 0.456 ± 0.149 g/cm(2) (-5.58 ± 1.79) in the femoral neck; and 0.316 ± 0.055 g/cm(2) (-5.85 ± 0.53) in radius 33. Patient 1 received oral alendronate, 30 mg/day for four weeks; his calcium decreased from 14 to 11.6 mg/dL, and his UDPD from 342 to 160 nmol/mmol Cr. Patient 2 received oral alendronate, 20 mg/day for six weeks; his calcium decreased from 14 to 11.0 mg/dL and his UDPD from 28.8 to 14 nmol/mmol Cr. Patient 3 received intravenous pamidronate, 90 mg prior to surgery. Patient 4 received oral alendronate, 140 mg/week for six weeks; her calcium decreased from 13.7 to 12.3 mg/dL and her CTX from 2,160 to 1,340 pg/mL. Patient 5 received oral alendronate, 140 mg/ week for six weeks; her calcium levels dropped from 14.3 to 14.1 mg/dL; her CTX did not change. Patient 6 received ibandronate, 150 mg, ten days prior to surgery; his CTX reduced by 62%. No patient developed severe hypocalcemia in the first postoperative week. One year after surgery, the mean gain in bone mineral density was 40% ± 29% in L2-L4, 86 ± 39% in the femoral neck, and 22% ± 11% in radius 33. The preoperative use of bisphosphonates seems to attenuate bone hunger without preventing a significant increase in bone mass in the follow-up of parathyroidectomy.


  • Characteristics of Paget’s disease of bone in the city of Recife, Brazil

    by Francisco Bandeira, Viviane Assunção, Erik Trovão Diniz, Cynthia Salgado Lucena, Luiz Griz


  • Open Access

    Novel nonsense mutation (p.Y113X) in the human growth hormone receptor gene in a Brazilian patient with Laron syndrome

    by Erik Trovão Diniz, Alexander A. L. Jorge, Ivo J. P. Arnhold, Arlan L. Rosenbloom, Francisco Bandeira

    BACKGROUND: To date, about sixty different mutations within GH receptor (GHR) gene have been described in patients with GH insensitivity syndrome (GHI). In this report, we described a novel nonsense mutation of GHR. METHODS: The patient was evaluated at the age of 6 yr, for short stature associated to clinical phenotype of GHI. GH, IGF-1, and GHBP levels were determined. The PCR products from exons 2-10 were sequenced. RESULTS: The patient had high GH (26 µg/L), low IGF-1 (22.5 ng/ml) and undetectable GHBP levels. The sequencing of GHR exon 5 disclosed adenine duplication at nucleotide 338 of GHR coding sequence (c.338dupA) in homozygous state. CONCLUSION: We described a novel mutation that causes a truncated GHR and a loss of receptor function due to the lack of amino acids comprising the transmembrane and intracellular regions of GHR protein, leading to GHI.